stockrowAlnylam Pharmaceuticals, Inc.
ALNY Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024.
- Revenue
- +16.7%
- EPS
- +747.6%
- Free cash flow
- −4.76%
- Total debt
- −2.66%
Quarter to September 2026, against a year earlier
Follow ALNY
Alert me
Alnylam Pharmaceuticals, Inc. (ALNY) Book value per share
Alnylam Pharmaceuticals, Inc.'s book value per share at the end of fiscal 2025 was 6.0×, up 1,046.1% from 0.5× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 26.9×. Over the past ten years it has ranged from −1.8× (fiscal 2023) to 19.5× (fiscal 2017); the current reading is higher than 45% of that period. Alnylam Pharmaceuticals, Inc. ranks 25th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 6.0× | 1,046.14% |
| FY2024 | 0.5× | — |
| FY2023 | −1.8× | — |
| FY2022 | −1.3× | — |
| FY2021 | 5.0× | (43.81%) |
| FY2020 | 8.8× | (32.88%) |
| FY2019 | 13.2× | 1.73% |
| FY2018 | 12.9× | (33.65%) |
| FY2017 | 19.5× | 81.45% |
| FY2016 | 10.8× | (28.60%) |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 26.9× | 165.70% |
| Jun 2026 | 10.1× | 25.25% |
| Mar 2026 | 8.1× | 35.59% |
| Dec 2025 | 6.0× | 235.40% |
| 43 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| BNTX BioNTech SE Sponsored ADR compare | 81.8× |
| JAZZ Jazz Pharmaceuticals PLC compare | 64.8× |
| INCY Incyte Corporation compare | 27.8× |
| ALNY Alnylam Pharmaceuticals, Inc. | 26.9× |
| ASND Ascendis Pharma A/S compare | 26.0× |
| EXEL Exelixis, Inc. compare | 7.4× |
| ROIV Roivant Sciences Ltd. compare | 6.8× |
| INSM Insmed, Inc. compare | 3.3× |
| BBIO BridgeBio Pharma, Inc. compare | −8.4× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on ALNY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement